Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1501 to 1515 of 7691 results

  1. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  2. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  3. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

  4. Avapritinib for treating advanced systemic mastocytosis (TA1012)

    Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.

  5. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

  6. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.

  7. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

  8. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

  9. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.

  10. Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)

    NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.

    Sections for TA994

  11. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  12. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  13. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

  14. Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

    NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

    Sections for TA148

  15. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.